Penile squamous cell carcinoma (PSCC) is a rare malignancy,
representing about 0.4 to 0.6% of all cancer cases and 2 to 4% of
genitourinary neoplasms diagnosed among males in the USA and
Europe [7]. The incidence rises with age, reaching its peak during
the sixth decade of life [8].
Main risk factors are Phimosis and poor hygiene, chronic
inflammation (like the licen sclerosus), PUVA therapy for
psoriasis, multiple sexual partners, and Human Papilloma Virus
(HPV) infection [9].
Penile cancer typically manifests with a skin abnormality or a
painless palpable lesion on the penis. Inguinal adenopathy is
observed in approximately 50% of cases at the time of diagnosis,
while distant metastases are uncommon during the initial
diagnosis, with only 1% to 10% of cases presenting with distant
metastases.
The initial diagnosis requires a biopsy for tissue confirmation and
risk stratification. Squamous cell carcinoma (SCC) accounts for
>95% of cases of primary penile cancer [8]. Penile squamous cell
carcinoma follows a predictable pattern of local and regional
metastasis, and lymph node metastasis being the most significant
predictor of survival [10]. The disease-specific survival rates for
patients with stage pN0, pN1, pN2, and pN3 disease are 96%,
80%, 66%, and 37%, respectively [11].
Therefore, following the confirmatory biopsy for primary tumor
assessment, the next step involves staging the disease through
clinical examination, imaging, pathologic assessment of the
primary tumor, and, if necessary, a diagnostic surgical lymph
node assessment. The TNM Staging System is employed for
staging PSCC and to establish prognostic staging for guiding
therapy. The preferred tests for tumor staging are ultrasound and
gadolinium-enhanced magnetic resonance imaging (MRI) [12].
Nodal status can be assessed using ultrasound, computed
tomography, MRI, and lymph node biopsy [13].